引用次数
引用: 1,502
H-指数: 19
I10-指数 : 29
出版物: 90
Ras signaling as a marker for application of oncolytic herpes mutant against lymphoma
F Farassati , N Atanaskova , C Raffel , P Johnston
MOLECULAR THERAPY 9 S26 -S26
1
2004
Ras activity as a marker for application of oncolytic Herpes SimplexVirus-1, R3616, in hematopoietic malignancies: Preferential infection of Raji but not Jurkat or Daudi cells by R3616
F Farassati , AD Yang , PWK Lee
CANCER GENE THERAPY 7 ( 12) S17 -S17
2000
RALA SIGNALING PATHWAY AS A TARGET FOR ANTI-CANCER THERAPY
KAORU TERAI , ZOHREH SANAAT , KAMYAR ASADIPOOYA , AYTEN GADASHOVA
( 21)
2013
ONCOLYTIC VIRUSES: A NOVEL CLASS OF ANTI-CANCER AGENTS AND THEIR APPLICATION IN TARGETING CANCER STEM CELLS
KAORU TERAI , ZHENGIAN LIU , ZOHREH SANAAT , KAMYAR ASADIPOOYA
2013
TARGETING MESOTHELIN IN TREATMENT OF HUMAN MALIGNANCES
FARIS FARASSATI
( 21)
2013
Diagnosis and treatment of herpes infections
An-Dao Yang , Patrick W. K. Lee , Faris Farassati
5
2001
Selective protein kinase C-β inhibitor (Enzastaurin) suppresses tumor growth, bone osteolysis, cancer -induced bone pain, and enhance radiosensitivity of the bone tumor.
Arkadiusz Dudek , Faris Farassati , Pawel Zwolak , Theresia Thalhammer
Clinical Cancer Research 12
2006
Silencing EGFRvIII as a therapeutic strategy against glioma
Vidya Bodempudi , Mary Mauzy , Arkadiusz Dudek , Robert Kratzke
Molecular Cancer Therapeutics 6
2007
Effect of EZH2 Inhibition on Colorectal Cancer Cells: an In Vitro Study
Farnia Ghafouri Sabzevari , Madjid Momeni-Moghaddam , Faris Farassati , Abolfazl Rad
Journal of Genetic Resources 2 ( 2) 88 -92
2016
Main Risk Factors Association with Proto-Oncogene Mutations in Colorectal Cancer
Reza Shabanloei , Mohammad Hossein Somi , Saeed Dastgiri , Roya Dolatkhah
Asian Pacific Journal of Cancer Prevention 19 ( 8) 2183 -2190
4
2018
Ras signalling pathway: a gateway for HSV-1 infection.
Faris Farassati , Patrick W.K. Lee
The Scientific World Journal 3 533 -535
6
2003
Transcription factors down-stream of Ras as molecular indicators for targeting malignancies with oncolytic herpes virus
Tuba Esfandyari , Ayalew Tefferi , Anna Szmidt , Tommy Alain
Molecular Oncology 3 ( 5) 464 -468
11
2009
RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC)
Elham Patrad , Kristina Lialyte , Kun Wang , Stephen Williamson
Molecular Oncology 8 ( 5) 1043 -1053
23
2014
Oncolytic viruses and cancer therapy
Kara L. Norman , Faris Farassati , Patrick W.K. Lee
Cytokine & Growth Factor Reviews 12 ( 2-3) 271 -282
30
2001
Differential modulation of malignant peripheral nerve sheath tumor growth by omega-3 and omega-6 fatty acids
George A Mashour , Stephanie N Drissel , Silke Frahm , Faris Farassati
Oncogene 24 ( 14) 2367 -2374
14
2005
Editorial announcing PubMed indexing of Oncolytic Virotherapy.
Faris Farassati
Oncolytic Virotherapy 6 19 -20
1
2017
Increased colorectal cancer incidence in Iran: a systematic review and meta-analysis
Roya Dolatkhah , Mohammad Hossein Somi , Iraj Asvadi Kermani , Morteza Ghojazadeh
BMC Public Health 15 ( 1) 997 -997
43
2015
Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes.
Weihong Pan , Farnaz Yamoutpour , Susann Henke , Mark Piedra
American Journal of Pathology 173 ( 6) 1861 -1872
29
2008
Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity
Farnaz Yamoutpour , Vidya Bodempudi , Shay E. Park , Weihong Pan
Molecular Cancer Therapeutics 7 ( 11) 3586 -3597
32
2008
Inhibition of Mesothelin as a Novel Strategy for Targeting Cancer Cells
Kun Wang , Vidya Bodempudi , Zhengian Liu , Emma Borrego-Diaz
PLoS ONE 7 ( 4) e33214
37
2012